Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT05601323
NA

A Study of Suizenji in Patients With Unresectable Pancreatic Cancer

Sponsor: SONIRE Therapeutics Inc.

View on ClinicalTrials.gov

Summary

The purpose of this study is to evaluate the safety and efficacy of standard chemotherapy with or without a novel High Intensity Focused Ultrasound system (Code: Suizenji) in patients with unresectable pancreatic cancer who are refractory or intolerant to first-line chemotherapy.

Official title: A Randomized Controlled Study of Suizenji in Patients With Unresectable Pancreatic Cancer

Key Details

Gender

All

Age Range

20 Years - Any

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2023-01-31

Completion Date

2027-05-31

Last Updated

2026-03-16

Healthy Volunteers

No

Interventions

DEVICE

Suizenji

HIFU treatment

DRUG

Nal-IRI/FL

Nanoliposomal irinotecan, Fluorouracil, Levofolinate

DRUG

mFOLFIRINOX

Fluorouracil, Levofolinate, Irinotecan, Oxaliplatin

DRUG

Gem/nab-PTX

Gemcitabine, nab-Paclitaxel

Locations (7)

Aichi Medical University Hospital

Nagakute-shi, Aichi, Japan

Tohoku University Hospital

Sendai-shi, Miyagi, Japan

Tokyo Medical University Hospita

Shinjuku-ku, Tokyo, Japan

Toyama University Hospital

Toyama-shi, Toyama, Japan

Wakayama Medical University Hospital

Wakayama-shi, Wakayama, Japan

Yokohama City University Medical Center

Yokohama-shi, Kanagawa, Japan

Kanagawa Cancer Center

Yokohama-shi, Kanagawa, Japan